Valsartan<\/strong><\/li>\n<\/ul>\nT\u00e1 d\u01b0\u1ee3c v\u1eeba \u0111\u1ee7 1 vi\u00ean.<\/p>\n
Tr\u00ecnh b\u00e0y<\/h3>\n
S\u0110K: 800110436223<\/p>\n
Quy c\u00e1ch \u0111\u00f3ng g\u00f3i: H\u00f4\u0323\u0323p 2 vi\u0309 x 14 vi\u00ean<\/p>\n
Xu\u1ea5t x\u1ee9: Italy<\/p>\n
UPERIO 50MG \u0111i\u1ec1u tr\u1ecb t\u00ecnh tr\u1ea1ng suy tim<\/figcaption><\/figure>\nT\u00e1c d\u1ee5ng c\u1ee7a thu\u1ed1c Uperio 50mg<\/h2>\nC\u01a1 ch\u1ebf t\u00e1c d\u1ee5ng<\/h3>\n\n- Uperio \u1ee9c ch\u1ebf \u0111\u1ed3ng th\u1eddi neprilysin v\u00e0 th\u1ee5 th\u1ec3 angiotensin II typ 1 (AT1).<\/li>\n
- Sacubitrilat (ch\u1ea5t chuy\u1ec3n h\u00f3a c\u1ee7a sacubitril) t\u0103ng n\u1ed3ng \u0111\u1ed9 c\u00e1c peptide natriuretic (NP) c\u00f3 l\u1ee3i, gi\u00fap gi\u00e3n m\u1ea1ch, l\u1ee3i ti\u1ec3u, t\u0103ng th\u1ea3i natri.<\/li>\n
- Valsartan \u1ee9c ch\u1ebf t\u00e1c \u0111\u1ed9ng c\u00f3 h\u1ea1i c\u1ee7a angiotensin II, gi\u1ea3m co m\u1ea1ch, gi\u1eef n\u01b0\u1edbc v\u00e0 mu\u1ed1i, ng\u0103n ch\u1eb7n t\u00e1i c\u1ea5u tr\u00fac tim.<\/li>\n
- Uperio \u0111\u00e3 \u0111\u01b0\u1ee3c ch\u1ee9ng minh l\u00e0m gi\u1ea3m NT-proBNP huy\u1ebft t\u01b0\u01a1ng (ch\u1ea5t ch\u1ec9 \u0111i\u1ec3m ph\u00f9 h\u1ee3p cho suy tim khi d\u00f9ng Uperio) v\u00e0 t\u0103ng BNP huy\u1ebft t\u01b0\u01a1ng.<\/li>\n<\/ul>\n
\u0110\u1eb7c \u0111i\u1ec3m d\u01b0\u1ee3c \u0111\u1ed9ng h\u1ecdc<\/h3>\n\n- H\u1ea5p thu: Sacubitril nhanh ch\u00f3ng chuy\u1ec3n h\u00f3a th\u00e0nh sacubitrilat. N\u1ed3ng \u0111\u1ed9 \u0111\u1ec9nh \u0111\u1ea1t \u0111\u01b0\u1ee3c sau 0,5 gi\u1edd (sacubitril), 2 gi\u1edd (sacubitrilat) v\u00e0 1,5 gi\u1edd (valsartan). Sinh kh\u1ea3 d\u1ee5ng \u0111\u01b0\u1eddng u\u1ed1ng c\u1ee7a sacubitril v\u00e0 valsartan l\u1ea7n l\u01b0\u1ee3t l\u00e0 \u2265 60% v\u00e0 23%.<\/li>\n
- Ph\u00e2n b\u1ed1: Li\u00ean k\u1ebft m\u1ea1nh v\u1edbi protein huy\u1ebft t\u01b0\u01a1ng (94% – 97%).<\/li>\n
- Chuy\u1ec3n h\u00f3a: Sacubitril chuy\u1ec3n h\u00f3a th\u00e0nh sacubitrilat. Valsartan chuy\u1ec3n h\u00f3a \u1edf m\u1ee9c t\u1ed1i thi\u1ec3u.<\/li>\n
- Th\u1ea3i tr\u1eeb: Ch\u1ee7 y\u1ebfu qua n\u01b0\u1edbc ti\u1ec3u v\u00e0 ph\u00e2n. 8 .Th\u1eddi gian b\u00e1n th\u1ea3i trung b\u00ecnh: sacubitril kho\u1ea3ng 1,43 gi\u1edd, sacubitrilat kho\u1ea3ng 11,48 gi\u1edd, valsartan kho\u1ea3ng 9,90 gi\u1edd.<\/li>\n<\/ul>\n
Thu\u1ed1c Uperio 50mg \u0111\u01b0\u1ee3c ch\u1ec9 \u0111\u1ecbnh trong b\u1ec7nh g\u00ec?<\/h2>\n\n- \u0110i\u1ec1u tr\u1ecb suy tim c\u00f3 tri\u1ec7u ch\u1ee9ng \u1edf b\u1ec7nh nh\u00e2n r\u1ed1i lo\u1ea1n ch\u1ee9c n\u0103ng t\u00e2m thu.<\/li>\n
- L\u00e0m gi\u1ea3m t\u1ef7 l\u1ec7 t\u1eed vong do b\u1ec7nh tim m\u1ea1ch v\u00e0 nh\u1eadp vi\u1ec7n do suy tim.<\/li>\n
- Gi\u1ea3m t\u1ef7 l\u1ec7 t\u1eed vong do m\u1ecdi nguy\u00ean nh\u00e2n.<\/li>\n<\/ul>\n
Li\u1ec1u d\u00f9ng v\u00e0 c\u00e1ch d\u00f9ng c\u1ee7a thu\u1ed1c Uperio 50mg<\/h2>\n\n- Li\u1ec1u kh\u1edfi \u0111\u1ea7u: 100 mg, hai l\u1ea7n\/ng\u00e0y (tr\u1eeb m\u1ed9t s\u1ed1 tr\u01b0\u1eddng h\u1ee3p \u0111\u1eb7c bi\u1ec7t).<\/li>\n
- Li\u1ec1u m\u1ee5c ti\u00eau: C\u00f3 th\u1ec3 t\u0103ng l\u00ean 200 mg, hai l\u1ea7n\/ng\u00e0y sau 2-4 tu\u1ea7n, t\u00f9y theo dung n\u1ea1p.<\/li>\n
- C\u00e1ch d\u00f9ng: U\u1ed1ng qua \u0111\u01b0\u1eddng mi\u1ec7ng, c\u00f3 th\u1ec3 d\u00f9ng c\u00f9ng ho\u1eb7c kh\u00f4ng c\u00f9ng th\u1ee9c \u0103n.<\/li>\n
- Quan tr\u1ecdng: Kh\u00f4ng d\u00f9ng Uperio c\u00f9ng v\u1edbi thu\u1ed1c \u1ee9c ch\u1ebf men chuy\u1ec3n (ACE). Ph\u1ea3i \u0111\u1ee3i \u00edt nh\u1ea5t 36 gi\u1edd sau khi ng\u1eebng ACEI m\u1edbi \u0111\u01b0\u1ee3c d\u00f9ng Uperio.<\/li>\n
- C\u1ea7n th\u1eadn tr\u1ecdng khi d\u00f9ng cho ng\u01b0\u1eddi cao tu\u1ed5i, b\u1ec7nh nh\u00e2n suy th\u1eadn, suy gan.<\/li>\n<\/ul>\n
Kh\u00f4ng s\u1eed d\u1ee5ng thu\u1ed1c Uperio 50mg trong tr\u01b0\u1eddng h\u1ee3p n\u00e0o?<\/h2>\n\n- Qu\u00e1 m\u1eabn v\u1edbi c\u00e1c th\u00e0nh ph\u1ea7n c\u00f3 trong thu\u1ed1c Uperio 50mg.<\/li>\n
- \u0110ang d\u00f9ng thu\u1ed1c \u1ee9c ch\u1ebf men chuy\u1ec3n (ACE) ho\u1eb7c trong v\u00f2ng 36 gi\u1edd sau khi ng\u1eebng ACEI.<\/li>\n
- Ti\u1ec1n s\u1eed ph\u00f9 m\u1ea1ch (s\u01b0ng ph\u00f9 nghi\u00eam tr\u1ecdng).<\/li>\n
- \u0110ang d\u00f9ng Aliskiren (\u0111\u1eb7c bi\u1ec7t \u1edf b\u1ec7nh nh\u00e2n ti\u1ec3u \u0111\u01b0\u1eddng ho\u1eb7c suy th\u1eadn).<\/li>\n
- Suy gan n\u1eb7ng, x\u01a1 gan m\u1eadt ho\u1eb7c \u1ee9 m\u1eadt.<\/li>\n
- Ph\u1ee5 n\u1eef c\u00f3 thai.<\/li>\n<\/ul>\n
L\u01b0u \u00fd \u0111\u1eb7c bi\u1ec7t khi s\u1eed d\u1ee5ng thu\u1ed1c Uperio 50mg<\/h2>\nTh\u1eadn tr\u1ecdng<\/h3>\n\n- C\u1ea7n theo d\u00f5i huy\u1ebft \u00e1p v\u00e0 n\u1ed3ng \u0111\u1ed9 kali m\u00e1u th\u01b0\u1eddng xuy\u00ean.<\/li>\n
- N\u1ebfu xu\u1ea5t hi\u1ec7n ph\u00f9 m\u1ea1ch, c\u1ea7n ng\u1eebng thu\u1ed1c ngay l\u1eadp t\u1ee9c v\u00e0 t\u00ecm ki\u1ebfm s\u1ef1 h\u1ed7 tr\u1ee3 y t\u1ebf.<\/li>\n<\/ul>\n
T\u00e1c d\u1ee5ng ph\u1ee5<\/h3>\n\n- C\u00e1c t\u00e1c d\u1ee5ng ph\u1ee5 ph\u1ed5 bi\u1ebfn nh\u1ea5t bao g\u1ed3m:<\/li>\n
- H\u1ea1 huy\u1ebft \u00e1p<\/li>\n
- T\u0103ng kali m\u00e1u<\/li>\n
- Suy gi\u1ea3m ch\u1ee9c n\u0103ng th\u1eadn<\/li>\n
- Ph\u00f9 m\u1ea1ch, ho, ch\u00f3ng m\u1eb7t, nh\u1ee9c \u0111\u1ea7u.<\/li>\n<\/ul>\n
T\u01b0\u01a1ng t\u00e1c<\/h3>\nT\u01b0\u01a1ng t\u00e1c ch\u1ed1ng ch\u1ec9 \u0111\u1ecbnh<\/h4>\n\n- C\u00e1c thu\u1ed1c \u1ee9c ch\u1ebf men chuy\u1ec3n angiotensin (ACE): T\u0103ng nguy c\u01a1 ph\u00f9 m\u1ea1ch.<\/li>\n
- Aliskiren: Ch\u1ed1ng ch\u1ec9 \u0111\u1ecbnh \u1edf b\u1ec7nh nh\u00e2n \u0111\u00e1i th\u00e1o \u0111\u01b0\u1eddng typ 2.<\/li>\n<\/ul>\n